Cantor Fitzgerald Reduces Earnings Estimates for Vaxcyte

Key Points

• Cantor Fitzgerald has decreased its FY2025 earnings per share estimate for Vaxcyte to ($5.50), down from ($5.10), while maintaining an "Overweight" rating on the stock.
• Vaxcyte reported a quarterly loss of ($1.22) EPS, which missed analysts' expectations of ($1.12), reflecting ongoing challenges in achieving profitability.
• Despite the downward revision in earnings estimates, Vaxcyte maintains a consensus rating of "Buy" from ten investment analysts, with a target price of $136.50.

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Vaxcyte in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst C. Gould now expects that the company will earn ($5.50) per share for the year, down from their previous estimate of ($5.10). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Cantor Fitzgerald also issued estimates for Vaxcyte's FY2026 earnings at ($7.28) EPS.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the business posted ($1.10) earnings per share.

Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Stock Down 0.4%

NASDAQ:PCVX opened at $29.90 on Monday. The stock's fifty day moving average is $34.43 and its two-hundred day moving average is $48.13. Vaxcyte has a 52 week low of $27.66 and a 52 week high of $121.06. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of -7.27 and a beta of 1.21.

Institutional Trading of Vaxcyte

Hedge funds have recently modified their holdings of the stock. National Bank of Canada FI acquired a new stake in shares of Vaxcyte in the fourth quarter valued at $41,000. AlphaQuest LLC acquired a new stake in shares of Vaxcyte in the first quarter valued at $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Vaxcyte in the first quarter valued at $35,000. Parallel Advisors LLC increased its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after buying an additional 1,071 shares during the last quarter. Finally, IFP Advisors Inc increased its holdings in Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after buying an additional 1,306 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.